MBX Biosciences, Inc.
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -6.60% | -2.05% | -11.37% | 18.71% | -53.21% |
| Total Depreciation and Amortization | -60.00% | 220.00% | -18.03% | -20.78% | 32.76% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 142.94% | 31.76% | 54.61% | 90.10% | 344.92% |
| Change in Net Operating Assets | -208.04% | 203.77% | -264.60% | 53.00% | 195.69% |
| Cash from Operations | -10.42% | 15.02% | -23.53% | 23.12% | -41.41% |
| Capital Expenditure | 44.89% | -98.75% | 43.56% | -2,256.67% | 67.39% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 25.17% | -840.07% | -34.61% | 719.81% | 104.84% |
| Cash from Investing | 25.29% | -862.04% | -34.36% | 705.52% | 104.79% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 9,095.08% | -99.49% | 14,083.86% | 33,050.00% | -97.95% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 26.89% | -103.54% | -- | -- | -- |
| Cash from Financing | 19,862.33% | -99.77% | 14,064.71% | 33,050.00% | 103.03% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 79.80% | -180.63% | 1,756.08% | 150.79% | 76.71% |